Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With or Without Ipilimumab as Consolidation Therapy in Stage III NSCLC
NCT03285321Phase 2Completed
- Start
- Sep 2017
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Nivolumab Alone with Nivolumab Plus Ipilimumab (2 arms). Primary endpoint: Progression Free Survival at 18 months. Started Sep 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03285321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285321.